Tenax Therapeutics will participate in the 2026 Cantor Global Healthcare Conference.
This follows the recent presentation of full results from its Phase 3 LEVEL clinical trial at the European Society of Cardiology Congress.
Trial data showed a benefit in a subgroup of patients. However, the trial missed its primary endpoint, creating some uncertainty.
Guggenheim downgraded the stock to "Neutral" from "Buy" following the data release. The firm cited ambiguity around clinical efficacy and the regulatory path forward.
The upcoming conference offers management an opportunity to address investor questions. Management will also clarify its strategy for levosimendan, its lead candidate.